Established biomarker quantification strategies for AD, including β-amyloid (Aβ) and tau measurements in cerebrospinal fluid (CSF) or amyloid or tau positron emission photography (PET) imaging, have been of limited use for screening because of invasiveness, high costs, and the need for specialized personnel. Here, MAPT is linked to Alzheimer disease.